MiR-205 Inhibits Cell Growth by Targeting AKT-mTOR Signaling in Progesterone-resistant Endometrial Cancer Ishikawa Cells

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 22

PMID 28427207

Citations 19

Authors

Zhihong Zhuo

Huimin Yu

Affiliations

Soon will be listed here.

Abstract

Purpose: miR-205 is significantly up-regulated in endometrioid adenocarcinoma. In this study, the significant anticancer effect of a miR-205 inhibitor was investigated in both endometrial carcinoma and progesterone-resistant endometrial carcinoma cells.

Results: Compared with Ishikawa endometrial cancer cells, miR-205 was expressed at higher levels in a progesterone-resistant (PR) sub-cell line. Inhibition of miR-205 suppressed the growth of cancer cells in a dose- and time-dependent manner. Moreover, the miR-205 inhibitor induced a marked increase in the percentage of Ishikawa-PR cells in G2/M phases and a decrease in the percentage of cells in G0/G1 and S phases. In addition, miR-205 inhibitor-treated tumor cells exhibited increased apoptosis. Moreover, miR-205 was found to negatively regulate PTEN expression and lead to autophagy and activation of the AKT/mTOR pathway in PR cells, and PTEN protein levels significantly decreased with development of progesterone resistance in endometrial cancer cells. Western blot assay showed up-regulated autophagy, as indicated by expression of LC3-II/LC3-I and beclin1, in Ishikawa cells; in particular, autophagy was markedly induced in PR cells treated with the miR-205 inhibitor.

Materials And Methods: We measured and analyzed cell growth curves with and without miR-205 inhibition with the MTT assay, miR-205 expression by qRT-PCR, cell cycle and apoptosis using annexin V/propidium iodide staining and flow cytometry, and autophagy, apoptosis, and AKT-mTOR signaling by western blotting.

Conclusions: Inhibition of miR-205, which targets the AKT-mTOR pathway, in endometrial cancer cells provides a potential, new treatment for PR endometrial carcinoma.

Citing Articles

The Roles of Autophagy-related miRNAs in Gynecologic Tumors: A Review of Current Knowledge for Possible Targeted Therapy.

Mobinikhaledi M, Faridzadeh A, Farkhondeh T, Pourhanifeh M, Samarghandian S Curr Mol Med. 2024; 24(10):1269-1281.

PMID: 39300715 DOI: 10.2174/0115665240263059231002093454.

Nanotherapeutics targeting autophagy regulation for improved cancer therapy.

Liu Y, Wang Y, Zhang J, Peng Q, Wang X, Xiao X Acta Pharm Sin B. 2024; 14(6):2447-2474.

PMID: 38828133 PMC: 11143539. DOI: 10.1016/j.apsb.2024.03.019.

Advances in research on autophagy mechanisms in resistance to endometrial cancer treatment.

Ji J, Cheng X, Du R, Xie Y, Zhang Y Front Oncol. 2024; 14:1364070.

PMID: 38601753 PMC: 11004244. DOI: 10.3389/fonc.2024.1364070.

Absolute Quantification of Selected microRNAs Expression in Endometrial Cancer by Digital PCR.

Bogaczyk A, Potocka N, Paszek S, Skrzypa M, Zuchowska A, Kosny M Int J Mol Sci. 2024; 25(6).

PMID: 38542261 PMC: 10969921. DOI: 10.3390/ijms25063286.

The Role of MicroRNAs in Development of Endometrial Cancer: A Literature Review.

Indumati S, Apurva B, Gaurav G, Nehakumari S, Nishant V J Reprod Infertil. 2023; 24(3):147-165.

PMID: 37663424 PMC: 10471942. DOI: 10.18502/jri.v24i3.13271.

References

Chen X, Zhang Z, Feng Y, Fadare O, Wang J, Ai Z . Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. Mod Pathol. 2009; 22(5):699-708. DOI: 10.1038/modpathol.2009.25. View

Mizushima N, Klionsky D . Protein turnover via autophagy: implications for metabolism. Annu Rev Nutr. 2007; 27:19-40. DOI: 10.1146/annurev.nutr.27.061406.093749. View

Diep C, Knutson T, Lange C . Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. Mol Cancer Res. 2015; 14(2):141-62. PMC: 4755896. DOI: 10.1158/1541-7786.MCR-15-0431. View

Blume-Jensen P, Hunter T . Oncogenic kinase signalling. Nature. 2001; 411(6835):355-65. DOI: 10.1038/35077225. View

Dong Y, Si J, Li W, Liang L, Zhao J, Zhou M . miR-200a/miR-141 and miR-205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas. Int J Clin Exp Pathol. 2015; 8(3):2864-75. PMC: 4440104. View

Mutter G, Lin M, Fitzgerald J, Kum J, Baak J, Lees J . Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000; 92(11):924-30. DOI: 10.1093/jnci/92.11.924. View

Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y . Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 2001; 167(1):39-48. DOI: 10.1016/s0304-3835(01)00462-1. View

Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T . Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci. 2009; 101(1):241-9. PMC: 11159282. DOI: 10.1111/j.1349-7006.2009.01385.x. View

Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W . MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One. 2012; 7(8):e41523. PMC: 3410899. DOI: 10.1371/journal.pone.0041523. View

10.

Tie J, Fan D . Big roles of microRNAs in tumorigenesis and tumor development. Histol Histopathol. 2011; 26(10):1353-61. DOI: 10.14670/HH-26.1353. View

11.

Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I . Endometrial cancer. Lancet. 2005; 366(9484):491-505. DOI: 10.1016/S0140-6736(05)67063-8. View

12.

Kimmelman A . The dynamic nature of autophagy in cancer. Genes Dev. 2011; 25(19):1999-2010. PMC: 3197199. DOI: 10.1101/gad.17558811. View

13.

Lee J, Park Y, Choi J, Lee Y, Kim C, Choi C . The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecol Oncol. 2010; 120(1):56-62. DOI: 10.1016/j.ygyno.2010.09.022. View

14.

Myatt S, Wang J, Monteiro L, Christian M, Ho K, Fusi L . Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 2009; 70(1):367-77. PMC: 2880714. DOI: 10.1158/0008-5472.CAN-09-1891. View

15.

Mutter G . Pten, a protean tumor suppressor. Am J Pathol. 2001; 158(6):1895-8. PMC: 1891981. DOI: 10.1016/S0002-9440(10)64656-1. View

16.

Risinger J, Hayes K, Maxwell G, Carney M, Dodge R, Barrett J . PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998; 4(12):3005-10. View

17.

Greene S, Gunaratne P, Hammond S, Rosen J . A putative role for microRNA-205 in mammary epithelial cell progenitors. J Cell Sci. 2010; 123(Pt 4):606-18. PMC: 2818197. DOI: 10.1242/jcs.056812. View

18.

Kim J, Kundu M, Viollet B, Guan K . AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011; 13(2):132-41. PMC: 3987946. DOI: 10.1038/ncb2152. View

19.

Yang Z, Klionsky D . Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol. 2009; 22(2):124-31. PMC: 2854249. DOI: 10.1016/j.ceb.2009.11.014. View

20.

Ratner E, Tuck D, Richter C, Nallur S, Patel R, Schultz V . MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol. 2010; 118(3):251-7. PMC: 2918705. DOI: 10.1016/j.ygyno.2010.05.010. View